Anzeige
Meldung des Tages: Kupfer vor dem Engpass: Warum Kupfer gerade zur „Nvidia“ unter den Rohstoffen wird

Biogen Aktie News

Aktie
WKN:  789617 ISIN:  US09062X1037 US-Symbol:  BIIB Branche:  Pharmazeutika Land:  USA
145,30 €
-2,45 €
-1,66%
22:27:02 Uhr
Depot/Watchlist
Marktkapitalisierung *
22,04 Mrd. €
Streubesitz
3,72%
KGV
11,76
neu: Nachhaltigkeits-Score
49 %
Index-Zuordnung
Nasdaq 100
Weiter abwärts? Short handeln - Jetzt mit Hebel 5,16: JU32NM
Werbung

Biogen News

13.10.25 - PR Newswire
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
LEQEMBI® IQLIK™(lecanemab-​irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" PR Newswire
09.10.25 - GlobeNewswire
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results ...
06.10.25 - GlobeNewswire
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
New LEQEMBI Companion ™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with ...
06.10.25 - PR Newswire
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-​irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease PR Newswire
03.10.25 - dpa-AFX
Erste Patienten bekommen Alzheimer-Mittel Lecanemab
Seit gut einem Monat ist das Alzheimer-​Medikament Lecanemab der Hersteller Biogen und Eisai in Deutschland verfügbar - inzwischen haben erste Patientinnen und Patienten mit ...
29.09.25 - GlobeNewswire
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate ...
25.09.25 - dpa-AFX
EU erteilt Zulassung für Alzheimer-Medikament von Eli Lilly
Für einen Teil der Menschen mit Alzheimer im Frühstadium gibt es in der EU eine weitere Behandlungsmöglichkeit. Die zuständige Europäische Kommission erteilte dem ...
24.09.25 - GlobeNewswire
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate ...
23.09.25 - GlobeNewswire
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete ...
18.09.25 - GlobeNewswire
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
Biogen to drive end-​to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs) ...
17.09.25 - GlobeNewswire
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Postpartum depression is a leading cause of maternal mortality in Europe 1-2 , and is one of the most common medical conditions associated with pregnancy 3-5 ; up to 20% of ...
17.09.25 - dpa-AFX
Biogen-Medikament gegen Wochenbettdepression in der EU zugelassen
Frauen mit Wochenbettdepression haben in der EU künftig Zugang zu einem neuen Medikament. Die Europäische Kommission hat Zuranolon vom US-​Konzern Biogen die EU-...
03.09.25 - GlobeNewswire
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-​amyloid treatment to offer at-home injection from the start to help patients and care partners treat this ...
02.09.25 - PR Newswire
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-​irmb) as a Subcutaneous Starting Dose for the Treatment of ...
02.09.25 - GlobeNewswire
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-​label ...
30.08.25 - dpa-AFX
Marktstart für Alzheimer-Mittel Lecanemab in Deutschland
Der zur Alzheimer-​Therapie zugelassene Antikörper Lecanemab kommt am 1. September in Deutschland offiziell auf den Markt. Österreich und Deutschland seien die ersten EU-...
30.08.25 - wallstreetONLINE Redaktion
Börsen-Nieten im Fokus: Diese 10 S&P-500-Aktien haben ein Jahrzehnt lang nur enttäuscht – bis jetzt!
Langfristige Verluste sind im S&P 500 eine Seltenheit – doch zehn Aktien haben in den vergangenen zehn Jahren klar enttäuscht. Welche dieser Nachzügler jetzt mit starken ...
29.08.25 - GlobeNewswire
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
LEQEMBI IQLIK is the first and only anti-​amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after ...
29.08.25 - PR Newswire
/U P D A T E -- Eisai Inc./
/U P D A T E -- Eisai Inc./ PR Newswire
25.08.25 - GlobeNewswire
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
– 3-year data from open-​label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and ...

Newssuche

Videos

newspaper
22.01.26 -5,56%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »